NCT05856513 is a Phase 1 clinical trial of ZSP1273 in Hepatic Impairment, sponsored by Guangdong Raynovent Biotech Co., Ltd.

Who is sponsoring NCT05856513?

NCT05856513 is sponsored by Guangdong Raynovent Biotech Co., Ltd.

What drugs are being tested in NCT05856513?

Interventions in NCT05856513: ZSP1273, ZSP1273, ZSP1273.

What condition does NCT05856513 study?

NCT05856513 studies Hepatic Impairment, Pharmacokinetics.

Is NCT05856513 still recruiting?

NCT05856513 is currently completed. Last updated 1 December 2023.

Last reviewed 2023-12-01 · How we verify

NCT05856513

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment

Completed Phase 1 Last updated 1 December 2023

What this trial tests

Phase 1 trial testing ZSP1273 in Hepatic Impairment in 24 participants. Completed in 4 July 2023.

Timeline

15 June 2023

Primary endpoint
4 July 2023

4 July 2023

Quick facts

Lead sponsor	Guangdong Raynovent Biotech Co., Ltd
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	24
Start date	15 June 2023
Primary completion	4 July 2023
Estimated completion	4 July 2023
Sites	1 location across China

Drugs / interventions tested

ZSP1273 — full drug profile →
ZSP1273 — full drug profile →
ZSP1273 — full drug profile →

Conditions studied

Hepatic Impairment — all drugs for Hepatic Impairment →
Pharmacokinetics — all drugs for Pharmacokinetics →

Sponsor

Guangdong Raynovent Biotech Co., Ltd — full company profile →

Who can join

Adults 18 to 68, any sex, with Hepatic Impairment or Pharmacokinetics. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of ZSP1273.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Single-Dose Tolerability and Pharmacokinetics of Onradivir in Chinese Patients with Hepatic Impairment and Healthy Matched Controls.
Li C, Li H, Mai J, Zhang H, et al · · 2025 · cited 5× · PMID 39287964 · DOI 10.1002/jcph.6134
Anti-influenza drugs targeting trimeric RNA polymerase complex: From development to clinics.
Li Y, Zhang J, He F, Cao C, et al · · 2026 · PMID 41685158 · DOI 10.1016/j.apsb.2025.11.033

Verify or expand the search:

Other trials of ZSP1273

Trials testing the same drug.

NCT07229807 — Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A · Phase 3 · active not recruiting
NCT07229820 — Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A · Phase 3 · active not recruiting
NCT06248567 — Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease · Phase 1 · completed
NCT06157450 — Pharmacokinetics of ZSP1273 in Elder Participants · Phase 1 · completed
NCT05954624 — Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid · Phase 1 · completed

Other recruiting trials for Hepatic Impairment

Currently open trials in the same condition.

NCT07269301 — A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function · Phase 1 · recruiting
NCT07219550 — A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017) · Phase 1 · recruiting
NCT07144111 — A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib · Phase 1 · recruiting
NCT07023354 — A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems · Phase 1 · recruiting
NCT06985615 — A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement · Phase 1 · recruiting

Other Guangdong Raynovent Biotech Co., Ltd trials

Trials by the same sponsor.

NCT07460284 — A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants · Phase 1 · not yet recruiting
NCT07229807 — Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A · Phase 3 · active not recruiting
NCT07229820 — Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A · Phase 3 · active not recruiting
NCT07139535 — A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone · Phase 3 · not yet recruiting
NCT07139548 — A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05856513 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Raynovent Biotech Co., Ltd
Last refreshed: 1 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05856513.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing